 This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of the combination of GSK573719 500mcg Inhalation Powder and GW642444 25mcg Inhalation Powder administered once-daily via a novel dry powder inhaler Novel DPI over 28 days in subjects with COPD 